Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumors
The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients ...
6 hours ago
0
0